CorriXR announces the appointment of Jill Castilla to our Board of Directors. She brings visionary leadership as a nationally recognized innovator in finance and banking. “We are thrilled to welcome Jill to our Board and believe she will be an invaluable asset with her vision and

Join us at Founders Who Flourish: A Look Inside The EIR Program event on 9/26 featuring Deborah Moorad, CEO of CorriXR and Blake Bixler, CEO of Senslytics. The event will be emceed by our very own Mansi Patel, Investment Analyst at Cortado Ventures. RSVP at the link in bio!

We look forward to sharing CorriXR's recent advances with CEO Deborah Moorad, CSO Eric B. Kmiec, and collaborators James Battiste and ChristianaCare Gene Editing Institute Kelly Banas #GeneEditing #Oncology

Advanced Therapies USA begins tomorrow! CorriXR CSO Eric Kmiec will be speaking about our novel #geneediting approach to overcoming drug resistance in #cancer treatment. Join our team and 1000 industry experts in cell and gene therapy at i.snoball.it/p/npwE/l/5 #adtherapiesusa

Don't miss the 11/27 webinar "Targeting Drug Resistance in Solid Tumors Using #CRISPR-Directed #GeneEditing" by our collaborator Kelly Banas of ChristianaCare Gene Editing Institute Sign up here: crisprmedicinenews.com/cmn-webinars/c…

CorriXR proudly announces the appointment of our founder Eric B Kmiec, Ph.D. as CEO. #genediting #CRISPR #oncology businesswire.com/news/home/2024…

CorriXR named one of 4 companies to watch in the accelerating #geneediting race by Clarivate PharmaVoice #CRISPR #Oncology #biotech pharmavoice.com/news/biotech-w…

Thrilled to announce that Jan Case has joined our team as COO. Her proven skills and expert guidance will help us achieve our goal of significantly improving the lives of people living with cancer. #CRISPR #geneediting #oncology #biotech businesswire.com/news/home/2025…

CorriXR welcomes Michael Alexander to our leadership team! #oncology #geneediting #biotech #CRISPR

Attending #CRISPRMED25? DM us to schedule a meeting with CorriXR Founder & CEO Eric B. Kmiec to learn more about our novel approach to treating solid tumors. #GeneEditing #CRISPR #oncology #biotech

Founder & CEO Eric Kmiec is presenting on the role #CRISPR can play in novel #oncology treatments at the CRISPR Medicine conference next week. We hope to see you there! #CRISPRMED25

CorriXR Founder & CEO Eric Kmiec, Ph.D. will be presenting at the BioNJ BioPartnering Conference next week. #BioPartnering2025 #oncology #CRISPR #biotech #geneediting

COO Jan Case will present CorriXR's next generation treatment for solid tumors at #BIO2025 on June 19 at 10:30 AM in Room 153B. #oncology #geneediting #CRISPR app.sosha.ai/s/dI66Jvzp

Attending #BIO2025? Don't miss CorriXR's presentation on our next generation treatment for solid tumors on June 19 at 10:30 AM in Room 153B. #oncology #geneediting #CRISPR

Exciting news! CorriXR has been selected to present our next generation treatment for solid tumors at the Life Sciences PA conference on Sept 25/26. #oncology #geneediting #CRISPR

Investing in Delaware’s innovators means investing in a healthier future. Newark-based CorriXR Therapeutics just received a $1M state grant to advance groundbreaking cancer gene-editing therapies—supporting local jobs, cutting-edge science, and life-saving treatments. Learn more: